The FDA recently expanded the approved uses of Avtozma (tocilizumab-anoh) intravenous (IV) infusion to include treatment of cytokine release syndrome (CRS) in adults and pediatric patients aged 2 years and older.

This expansion marks a significant development in managing a potentially life-threatening immune condition affecting patients undergoing certain advanced therapies, especially children receiving chimeric antigen receptor (CAR) T-cell treatments.

Originally approved earlier this year for multiple inflammatory conditions, including rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis and COVID-19-related inflammation, Avtozma now aligns fully with the FDA-approved indications of its biosimilar, Actemra.

This approval is an additional treatment option for CRS,

See Full Page